{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:17:09Z","timestamp":1794608229293,"version":"4.9.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Male-to-female (MtF) transgender individuals are at risk for prostate cancer, although guidelines for screening and management in this population are not well established. We describe a series of 9 MtF transgender patients who underwent prostate tissue sampling and highlight histopathologic features and challenges related to pathologic interpretation of prostate tissue in this patient population. Seven of 9 total patients were diagnosed with prostate cancer and all had elevated prostate-specific antigen at the time of diagnosis. Three of the 7 patients diagnosed with prostate cancer had received different types of hormone therapy for gender affirmation before the diagnosis of prostate cancer, and in all 3 of these patients, there was histologic evidence of hormone therapy effect in both benign prostate tissue and\/or the adenocarcinoma. The 2 patients with benign prostate tissue underwent transurethral resection for lower urinary tract symptoms and were previously on hormone therapy for gender affirmation. Both of these specimens showed diffuse glandular atrophy and basal cell hyperplasia, indicative of hormone therapy effect on benign prostatic tissue. In the patients diagnosed with prostate cancer, a spectrum of grades was observed, ranging from Grade Group 1 to Grade Group 5. Four patients underwent radical prostatectomy, with 2 cases showing extraprostatic extension and Grade Group 5 prostatic adenocarcinoma, and 2 showing Grade Group 2 prostatic adenocarcinoma. Three of the 4 patients who underwent radical prostatectomy had received gender-affirming hormone therapy before surgery, and all 3 of these specimens showed hormone therapy effect in non-neoplastic prostate tissue and focal hormone therapy effect in prostatic adenocarcinoma. The presence of areas of viable carcinoma without hormone therapy effect enabled the assignment of a Gleason score and Grade Group in these 3 cases. Hormone therapy administered for gender identity affirmation induces histopathologic changes to both benign prostate tissue (nonkeratinizing squamous metaplasia, diffuse atrophy, basal cell hyperplasia, and stromal dominance with decreased numbers of glands) and prostatic adenocarcinoma (nuclear pyknosis, atrophy, cytoplasmic vacuolization, and architectural patterns that would qualify for Gleason 4 and 5 in the absence of hormone therapy effect) that have been traditionally seen in cis-male prostate cancer patients receiving hormone therapy. In the absence of hormone therapy, the morphology of prostatic adenocarcinoma in transgender patients shows classic morphologic features similar to those seen in cis-male patients not on hormone therapy. Prostate cancer with hormone therapy effect may not only be histologically quite subtle and may be overlooked if not suspected, but also should not be assigned a Gleason score because the Gleason score would substantially overstate its biologic potential. Therefore, similar to cis-male patients who have received androgen deprivation therapy for prostate cancer, transgender patients on hormone therapy for gender affirmation may be at risk for both underrecognition and over-grading of prostate cancer, particularly if the pathologist is not aware of the clinical history.<\/jats:p>","DOI":"10.1097\/pas.0000000000001964","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T17:00:09Z","timestamp":1661446809000},"page":"1650-1658","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Prostate Cancer in Male-to-Female Transgender Individuals"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6932-8985","authenticated-orcid":false,"given":"Ezra","family":"Baraban","sequence":"first","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Kuang C.","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"White","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Vohra","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffry","family":"Simko","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Boyle","sequence":"additional","affiliation":[{"name":"Chesapeake Urology, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pathology, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Dobs","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvethavarshini","family":"Ketheeswaran","sequence":"additional","affiliation":[{"name":"Plastic Surgery, Johns Hopkins Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Liang","sequence":"additional","affiliation":[{"name":"Plastic Surgery, Johns Hopkins Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Epstein","sequence":"additional","affiliation":[{"name":"Pathology"},{"name":"Urology"},{"name":"Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.21037\/tau-20-954","article-title":"Cancer screening in the transgender population: a review of current guidelines, best practices, and a proposed care model","volume":"9","author":"Sterling","year":"2020","journal-title":"Transl Androl Urol"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatmentof gender-dysphoric\/gender-incongruent persons: an endocrine society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"R3-20250608","first-page":"30","article-title":"Transgender care in theprimary care setting: a review of guidelines and literature","volume":"35","author":"Hashemi","year":"2018","journal-title":"Fed Pract"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bju.15521","article-title":"Gender Research Collaborative. Prostate cancer in transgender women: what does a urologist need to know?","volume":"129","author":"Bertoncelli Tanaka","year":"2022","journal-title":"BJU Int"},{"key":"R5-20250608","first-page":"35","article-title":"Gynaecological aspects of the treatment and follow-up of transsexual men and women","volume":"2","author":"Weyers","year":"2010","journal-title":"Facts Views Vis Obgyn"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/pros.23322","article-title":"The development of prostate adenocarcinoma in a transgender male to female patient: could estrogen therapy have played a role?","volume":"77","author":"Sharif","year":"2017","journal-title":"Prostate"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1001\/jama.296.19.2316","article-title":"Prostate cancer in a transgender woman 41 years after initiation of feminization","volume":"296","author":"Miksad","year":"2006","journal-title":"JAMA"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"E544","DOI":"10.5489\/cuaj.175","article-title":"Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy","volume":"7","author":"Turo","year":"2013","journal-title":"Can Urol Assoc J"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"e3293","DOI":"10.1210\/clinem\/dgaa412","article-title":"Prostate cancer incidence under androgen deprivation: nationwide cohort study in trans women receiving hormone treatment","volume":"105","author":"de Nie","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0022-5347(01)65584-8","article-title":"Effects of estrogens only on the prostates of aging men","volume":"156","author":"van Kesteren","year":"1996","journal-title":"J Urol"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s11930-019-00234-7","article-title":"Understanding prostate cancer in gay, bisexual, and other men who have sex with men and transgender women: a review of the literature","volume":"11","author":"Rosser","year":"2019","journal-title":"Curr Sex Health Rep"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.urology.2017.08.032","article-title":"Prostate cancer in transgender women: incidence, etiopathogenesis, and management challenges","volume":"110","author":"Deebel","year":"2017","journal-title":"Urology"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.urolonc.2018.09.011","article-title":"Prostate cancer in transgender women","volume":"36","author":"Ingham","year":"2018","journal-title":"Urol Oncol"},{"issue":"pt 1","key":"R14-20250608","first-page":"429","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian uro-oncological study group","volume":"154","author":"Van Poppel","year":"1995","journal-title":"J Urol"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41391-017-0009-6","article-title":"Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade","volume":"21","author":"McKay","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/1097-0142(19910815)68:4<821::AID-CNCR2820680426>3.0.CO;2-S","article-title":"Pathologic changes associated with androgen deprivation therapy for prostate cancer","volume":"68","author":"Murphy","year":"1991","journal-title":"Cancer"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2559.2011.04079.x","article-title":"Therapy-associated effects in the prostate gland","volume":"60","author":"Srigley","year":"2012","journal-title":"Histopathology"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1071\/RD01010","article-title":"Estrogenic effects on prostatic differentiation and carcinogenesis","volume":"13","author":"Cunha","year":"2001","journal-title":"Reprod Fertil Dev"},{"key":"R19-20250608","first-page":"293","article-title":"Studies in prostatic cancer. I. The effects of castration, of estrogen and of androgen injection of serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00000478-199803000-00010","article-title":"Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy","volume":"22","author":"Tran","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/jcp.51.11.878a","article-title":"Pseudomyxoma ovariilike posttherapeutic alteration in prostate adenocarcinoma","volume":"51","author":"Beer","year":"1998","journal-title":"J Clin Pathol"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/1097-0142(19940301)73:5<1472::AID-CNCR2820730525>3.0.CO;2-M","article-title":"Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation","volume":"73","author":"Smith","year":"1994","journal-title":"Cancer"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/pros.2990070209","article-title":"Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy","volume":"7","author":"Grignon","year":"1985","journal-title":"Prostate"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.eururo.2009.10.020","article-title":"Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification","volume":"57","author":"Efstathiou","year":"2010","journal-title":"Eur Urol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/pros.23777","article-title":"Differential response to neoadjuvant hormonal therapy in prostate cancer: predictive morphological parameters and molecular markers","volume":"79","author":"Wang","year":"2019","journal-title":"Prostate"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/PAP.0000000000000347","article-title":"Neoadjuvant hormonal therapy for prostate cancer: morphologic features and predictive parameters of therapy response","volume":"29","author":"Wang","year":"2022","journal-title":"Adv Anat Path"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.eurpsy.2015.04.005","article-title":"Systematic review and meta-analysis of prevalence studies in transsexualism","volume":"30","author":"Arcelus","year":"2015","journal-title":"Eur Psychiatry"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:03:14Z","timestamp":1749416594000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001964"}},"subtitle":["Histopathologic Findings and Association With Gender-affirming Hormonal Therapy"],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001964","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,26]]}}}